Trial Profile
A Phase 1/2 Open Label Study of SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 15 Nov 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Pomalidomide (Primary) ; Tagraxofusp (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Stemline Therapeutics
- 13 Jan 2022 Status changed from completed to discontinued.
- 14 Dec 2021 Early results of translational correlative studies using bone marrow (BM), peripheral blood (PB), and serum from this study cohort presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 08 Dec 2020 Initial results of correlative science studies using bone marrow (BM), peripheral blood (PB), and serum from this study cohort (n=9), were presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.